|
|
|
|
Targeting diseases at their genetic root, cell and gene therapies offer unprecedented hope. Yet, the industry grapples with balancing groundbreaking potential against the challenge of high-priced treatments.
|
|
|
|
|
For innovative treatments like CAR-T and stem cell transplants, optimal starting material is key. Understanding collection challenges and new solutions helps ensure the best foundation for these therapies.
|
|
|
|
|
Automation enhances efficiency and minimizes contamination risks and labor costs. Despite the initial investment in automation equipment, the long-term savings can be significant. Explore how progress in automation could potentially expand the accessibility and benefits of T-cell therapies to a larger patient population.
|
|
|
|
|
New advances are making it possible to produce high-quality T cells at scale. Learn how automation and refining manufacturing processes are solving the historic trade-off between the quality and quantity of these vital cell therapies.
|
|
|
|
|
Artificial Intelligence is essential for optimizing cell and gene therapy manufacturing. Learn how quality, real-time data from advanced analytics tools is enabling tighter process control and accelerating time to market.
|
|
|
